Otonomy Inc. (OTIC) and Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) Comparing side by side

Otonomy Inc. (NASDAQ:OTIC) and Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Otonomy Inc. N/A 119.17 50.93M -1.66 0.00
Diffusion Pharmaceuticals Inc. N/A 0.00 17.80M -8.68 0.00

Demonstrates Otonomy Inc. and Diffusion Pharmaceuticals Inc. earnings per share (EPS), gross revenue and valuation.

Profitability

Table 2 demonstrates the net margins, return on assets and return on equity of Otonomy Inc. and Diffusion Pharmaceuticals Inc.

Net Margins Return on Equity Return on Assets
Otonomy Inc. 0.00% -60.1% -48.1%
Diffusion Pharmaceuticals Inc. 0.00% -83.8% -74.6%

Risk & Volatility

A beta of 2.42 shows that Otonomy Inc. is 142.00% more volatile than Standard and Poor’s 500. Diffusion Pharmaceuticals Inc.’s 106.00% less volatile than Standard and Poor’s 500 which is a result of the -0.06 beta.

Analyst Ratings

Recommendations and Ratings for Otonomy Inc. and Diffusion Pharmaceuticals Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Otonomy Inc. 0 0 1 3.00
Diffusion Pharmaceuticals Inc. 0 0 0 0.00

Otonomy Inc.’s average target price is $5, while its potential upside is 102.43%.

Institutional and Insider Ownership

Otonomy Inc. and Diffusion Pharmaceuticals Inc. has shares held by institutional investors as follows: 65.9% and 8.6%. Insiders held 0.28% of Otonomy Inc. shares. Competitively, Diffusion Pharmaceuticals Inc. has 3.37% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Otonomy Inc. -6.17% 3.58% 40.29% 16.53% -36.48% 56.22%
Diffusion Pharmaceuticals Inc. 0.22% 39.38% 80.48% -8.79% -37.08% 127.64%

For the past year Otonomy Inc.’s stock price has smaller growth than Diffusion Pharmaceuticals Inc.

Summary

Otonomy Inc. beats Diffusion Pharmaceuticals Inc. on 5 of the 8 factors.

Otonomy, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for diseases and disorders of the ear in the United States. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. OTIPRIO has also completed a Phase III clinical trial for treating swimmer’s ear and a Phase II clinical trial for treating acute otitis media with tubes. The company also develops OTO-104, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière’s disease and other inner ear conditions; and OTO-311, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed a Phase 1 clinical safety trial for the treatment of tinnitus. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.

Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, developing small-molecule drugs that help regulate the movement of oxygen into tissue by a novel mechanism of action. Its lead product candidate is trans sodium crocetinate, which is in Phase I/II clinical trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of pancreatic cancer; and Phase II/III clinical trials for the treatment of metastatic brain cancer. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of macular degeneration; and is in pre-clinical development in oncology applications primarily GBM. Diffusion Pharmaceuticals Inc. is headquartered in Charlottesville, Virginia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.